Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Hvidovre University Hospital

Status: Completed

Conditions: Type 2 Diabetes Mellitus

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02201550

H-2-2012-148-KLB

Details and patient eligibility

About

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.

The hypotheses are:

• Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood
• Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood
• Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Enrollment: 9 patients

Sex: Male

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• BMI > 27 kg/m2
• Planed start of treatment with liraglutide
• Age > 18 years

Exclusion criteria

• Infection or active inflammatory disorder
• Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
• Smoking
• Alcohol consumption > 14 beverages/week
• Former bariatric surgery

Trial design

9 participants in 1 patient group

Liraglutide

Description:

Patients with type 2 diabetes undertaking treatment with liraglutide